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Secondary metabolites produced by Actinobacteria serve a variety of functions including molecules having 
agricultural applications.  Streptomyces sp. 517-02 produces a novel fungicidal compound called UK-2A, which 
through a single step chemical reaction is converted to Inatreq™ active. Inatreq utilizes a unique target site of 
action, ubiquinone reductase Qi site (inner side of membrane), and is intended for use in cereals and banana 
markets with strong residual protectant and curative activity in wheat against Zymoseptoria tritici, with additional 
activity on rust and other diseases. To achieve a commercially viable process an integrated multidiscipline 
approach was applied in parallel including mutagenesis, high-throughput (HTP) screening, fermentation process 
optimization, and targeted genetic engineering.  The presentation will review how the integrated approach 
contributed to a rapid acceleration in productivity gains resulting in a 75% improvement in titer over a one-year 
period, more than a 2 fold improvement in 4 years and successful scale-up to the final commercial production 
plant. 
 
Examples of topics to be discussed: 
 Development, deployment, and optimization of the mutagenesis and high-throughput screening process 
for the selection of improved strains. 
 Deployment of targeted genetic engineering to alleviate biosynthesis bottlenecks identified using 
approaches such as biosynthetic gene overexpression and precursor feeding. 
 Use of “omics” tools to identify native promoters which permit temporal gene expression suitable for 
enhanced precursor production and increased UK-2A production. 
 Vetting of new strains and fermentation process improvements both in bioreactors at multiple scales and 
in the downstream process for product recovery. 
 Use of experimental results from across the integrated program to guide prioritization of strain and 
process improvement targets.  
 Incorporation of final product design and performance requirements into the program with a line of sight 
to manufacturing process constraints. 
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